Pluribus Labs’s CONMED CNMD Stock Holding History

Pluribus Labs’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,856	Closed	-$263K	–	89
2021 Q4	$263K	Buy	+1,856	New	+$263K	0.28%	156

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Pluribus Labs's CNMD Position: Q1 2022 in Review

Pluribus Labs sold out of CONMED (CNMD) in Q1 2022, closing a stake of 1,856 shares — an estimated $263K sold.

Pluribus Labs first reported a position in CNMD in Q4 2021 and held it in 1 quarter. The position peaked at $263K in Q4 2021. 281 funds tracked by Wall St. Rank hold CNMD as of Q1 2022.

Pluribus Labs reported no remaining CONMED position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 1,856 CONMED shares in Q1 2022, an estimated $263K.
Pluribus Labs first reported a position in CONMED in Q4 2021 and held it in 1 quarter.
Pluribus Labs's CONMED position peaked at $263K in Q4 2021.
281 funds tracked by Wall St. Rank held CONMED as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.